Last reviewed · How we verify
Modified Release rhTSH
At a glance
| Generic name | Modified Release rhTSH |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter (PHASE2)
- Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Modified Release rhTSH CI brief — competitive landscape report
- Modified Release rhTSH updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI